DIRS.INFO The most relevant business & tech news

A general view of the drug product manufacturing laboratory in biologics and sterile injectables, Catalent, in Brussels, Belgium June 27, 2023. Spokespeople for Catalent and Elliott declined to comment. The U.S.-based contract drugmaker is also Danish company Novo Nordisk's (NOVOb.CO) main manufacturing partner for its popular weight-loss drug Wegovy. The volatility at Catalent could increase scrutiny on the relationship between Novo and its partner. Reuters reported last week that a second Catalent factory will begin filling Wegovy injection pens for Novo as part of an expanded supply agreement.

Persons: Yves Herman Acquire, Elliott, drugmaker, Markus Manns, Catalent, Elliott isn't, Keith Meister's, Scott Ferguson's, Mauricio Gutierrez, Svea Herbst, Bayliss, Maggie Fick, Amanda Cooper, Shri Navaratnam, Bernadette Baum, Catherine Evans Organizations: REUTERS, Elliott Investment Management, Catalent, Novo, Reuters, Union Investment, AstraZeneca, Johnson, Moderna, eBay, Inc, Deutsche Bank, Management, Capital Management, NRG, Svea, Thomson Locations: Brussels, Belgium, U.S, Danish, Novo, United States, Germany, Boston, London

☆ Some Older Adults Are Being Charged Over $300 for the New R.S.V. Vaccine
▼ + stars: | 2023-08-25 | by ( Dana G. Smith | More About Dana G. Smith | ) www.nytimes.com time to read: +1 min

Amanda Jaffe, 69, went to her local pharmacy at the Safeway in Helena, Mont., to get the R.S.V. Upon hearing the price (over $300), Ms. Jaffe thought “that’s ridiculous” and left without getting it. Several common vaccines, including those for the flu and Covid-19, are included under Medicare Part B, which provides medical coverage. vaccines, as well as a few others, including the vaccine for shingles, are covered under Medicare Part D, which pays for prescription drugs. As a result, Medicare enrollees without a Part D plan — roughly 16 million people — may have to pay for the R.S.V.

Persons: Amanda Jaffe, “, ” Ms, Jaffe, ”, Richard Hughes IV, Epstein Becker Green Organizations: Safeway, Medicare, Moderna, Centers, Medicaid Services, New York Times Locations: Helena, Mont

☆ Updated Covid-19 vaccines are coming mid-September, officials say
▼ + stars: | 2023-08-25 | by ( Brenda Goodman | ) edition.cnn.com time to read: +5 min

CNN —Covid-19 vaccines that have been tweaked to teach the body how to fend off the current crop of circulating variants are now expected to land in drugstores and clinics in mid-September, senior administration officials say. The US Food and Drug Administration is expected to give its nod to the updated vaccines in a few weeks. Officials said ACIP will meet quickly after the FDA decision in order to expedite the regulatory steps and get the vaccines to market. The advisory group is scheduled to meet to discuss Covid-19 vaccines on September 12, meaning the vaccines could become available soon after. The details of the pharmacy program are still being worked out, and there may be a slight lag in getting free vaccines at some stores.

Persons: CNN —, ACIP, Mandy Cohen, ”, Dr, Sanjay Gupta, Cohen, There’s Organizations: CNN, US Food and Drug Administration, US Centers for Disease Control, Officials, CDC, Covid, Pfizer, Moderna, FDA, EG, Affordable, CVS, Walgreens, Walmart, CNN Health Locations: drugstores, Covid

☆ CDC expects new Covid vaccines from Pfizer, Moderna and Novavax to be available in mid-September
▼ + stars: | 2023-08-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

The Centers for Disease Control and Prevention expects updated Covid vaccines from Pfizer , Moderna and Novavax to be available to the public in mid-September, an agency official told reporters Thursday. CDC Director Mandy Cohen had previously provided a later timeline, telling NPR that the vaccines could be available by the "early October time frame." Those shots still need approvals from the Food and Drug Administration and the CDC, which will set eligibility guidelines for the jabs. Officials from the CDC and FDA said the agencies will encourage Americans to receive an updated Covid shot and other key vaccines ahead of the fall, when respiratory viruses typically begin to spread more widely. "Our goal, our imperative, our task is to make sure we're using those tools," the CDC official said.

Persons: Mandy Cohen Organizations: Disease Control, Pfizer, Moderna, Federal, NPR, Food and Drug Administration, CDC, FDA

☆ Goldman says these stocks have produced the best risk-adjusted returns for mutual funds
▼ + stars: | 2023-08-24 | by ( Yun Li | ) www.cnbc.com time to read: +1 min

Mutual fund managers have been able to generate alpha outside of Big Tech this year, with some stocks contributing sizable gains, according to Goldman Sachs. Goldman found the large-cap core have struggled this year due to their underweight in the largest tech stocks, which have led the market rally. However, mutual fund managers were able to find winners elsewhere, Goldman said. "An improving stock picking environment has helped mutual fund PMs generate alpha elsewhere in their portfolios," Goldman strategists said in a note. Top gainers in mutual fund portfolios also included energy stocks Chevron , Exxon Mobil and NextEra Energy.

Persons: Goldman Sachs, Goldman, Russell, — CNBC's Michael Bloom Organizations: Big Tech, Alpha, Pfizer, Johnson, Moderna, Chevron, Exxon Mobil, NextEra Energy

☆ US CDC says new COVID lineage could cause infections in vaccinated individuals
▼ + stars: | 2023-08-23 | by ( ) www.reuters.com time to read: +1 min

CDC said it was too soon to know whether this might cause more severe illness compared with previous variants. But due to the high number of mutations detected in this lineage, there were concerns about its impact on immunity from vaccines and previous infections, the agency said. Scientists are keeping an eye on the BA.2.86 lineage because it has 36 mutations that distinguish it from the currently-dominant XBB.1.5 variant. The agency had earlier this month said it was tracking the highly mutated BA.2.86 lineage, which has been detected in the United States, Denmark and Israel. CDC said on Wednesday the current increase in hospitalizations in the United States is not likely driven by the BA.2.86 lineage.

Persons: Pratik Jain, Shilpi Majumdar Organizations: Science, Trinity College, Reuters, U.S . Centers for Disease Control, Prevention, CDC, Thomson Locations: Dublin, Wuhan, United States, Denmark, Israel, hospitalizations, Bengaluru

☆ Novavax shares surge after drugmaker says new Covid vaccine was effective against Eris variant
▼ + stars: | 2023-08-22 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Shares of Novavax jumped more than 13% on Tuesday after the biotech company said its new Covid vaccine generated a broad immune response against the now-dominant Eris variant and another fast-spreading strain of the virus in small animal trials. But the trial results suggest that the shot may still be effective against newer Covid variants gaining a greater foothold in the U.S. That includes Eris and XBB.1.16.6, both of which are also descendants of omicron. "We have a lot of confidence in our updated Covid vaccine and are working diligently with global regulatory bodies to ensure our protein-based vaccine is available this fall," Filip Dubovsky, Novavax's president of research and development, said in a release. The World Health Organization designated Eris a "variant of interest," meaning it will be monitored for mutations that could make it more severe. XBB.1.16.6 is also beginning to surge, accounting for 8% of all cases nationwide as of Saturday, the CDC said.

Persons: Novavax, Filip Dubovsky Organizations: Pfizer, Moderna, U.S . Food, Drug Administration, EG, Centers for Disease Control, World Health Organization, CDC Locations: U.S, hospitalizations

☆ Covid vaccine stocks jump as new variants emerge ahead of fall shot rollout
▼ + stars: | 2023-08-21 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Covid vaccine makers' shares rose Monday as new variants of the virus emerge in the U.S. ahead of the rollout of updated shots this fall. Shares of BioNTech , which jointly develops Covid vaccines with Pfizer , popped nearly 7%. It's been a rocky few months for those stocks as sales of Covid shots and treatments plummet in the U.S.: Shares of all four companies are down more than 20% for the year. But Wall Street's enthusiasm for Covid vaccine makers is getting a fresh boost with the upcoming launch of brand-new shots this fall and the emergence of new variants of the virus. So far, there is no evidence that BA.2.86 spreads faster or causes more serious infections than previous versions.

Persons: Novavax, It's Organizations: Pfizer, EG, U.S . Health, CNBC, Moderna, Novavax, World Health Organization, U.S . Centers for Disease Control, Prevention Locations: U.S, Denmark, Israel

☆ Biden administration to urge Americans get new COVID-19 boosters
▼ + stars: | 2023-08-20 | by ( ) www.reuters.com time to read: +1 min

A 50-year-old and immunocompromised resident receives a second booster shot of the coronavirus disease (COVID-19) vaccine in Waterford, Michigan, U.S., April 8, 2022. On Thursday, Moderna (MRNA.O) said initial data showed its updated COVID-19 vaccine is effective against the "Eris" and "Fornax" subvariants in humans. Moderna and other COVID-19 vaccine makers Novavax (NVAX.O), Pfizer (PFE.N) and German partner BioNTech SE (22UAy.DE) have created versions of their shots aimed at the XBB.1.5 subvariant. Pending approval from health regulators in the United States and Europe, the companies expect the updated shots to be available in the coming weeks for the autumn vaccination season. "We will be encouraging all Americans to get those boosters in addition to flu shots and RSV shots," the official said, referring to the Respiratory Syncytial Virus.

Persons: Emily Elconin, Biden, BioNTech, Steve Holland, Lisa Shumaker Organizations: REUTERS, Rights, White, for Disease Control, Pfizer, Thomson Locations: Waterford , Michigan, U.S, Moderna, United States, Europe

Scientists are keeping an eye on the new lineage, named BA.2.86, because it has 36 mutations that distinguish it from the currently-dominant XBB.1.5 variant. So far there is no evidence that BA.2.86 spreads faster or causes more serious illness than previous versions. COVID infections and hospitalizations have been rising in the U.S., Europe and Asia, with more cases in recent months attributed to the EG.5 "Eris" subvariant, a descendant of the Omicron lineage that originally emerged in November 2021. But many countries have drastically reduced testing of patients and their efforts to analyze the genomes of the viruses causing new COVID cases. Updated COVID booster shots now being developed have been designed to target the Omicron subvariant XBB.1.5.

Persons: Emily Elconin, Wesley Long, Eric Topol, Topol, Long, Moderna, Eris, Deena Beasley, Nancy Lapid, David Gregorio Our Organizations: REUTERS, Moderna Inc, Pfizer, World Health Organization, U.S . Centers for Disease Control, CDC, EG, Omicron, Houston Methodist Hospital, Scripps Research, COVID, U.S, Pfizer Inc, Thomson Locations: Waterford , Michigan, U.S, Europe, Asia, United States, Israel, Denmark, La Jolla , California

☆ New Covid vaccines from Pfizer, Moderna and Novavax will likely protect against Eris variant
▼ + stars: | 2023-08-18 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

New Covid vaccines from Pfizer , Moderna and Novavax will likely provide protection against the new "Eris" variant, now the dominant strain of the virus in the U.S. The drugmakers designed their updated vaccines to target the omicron subvariant XBB.1.5, which is slowly declining nationwide. Eris accounted for 17.3% of all cases in the U.S. as of earlier this month, according to the latest data from the CDC. The World Health Organization earlier this month designated Eris a "variant of interest," meaning it will be monitored for mutations that could potentially make it more severe. It's also not expected to cause a huge wave of Covid cases like other strains have in previous years.

Persons: Dr, Mark Mulligan, It's Organizations: Chicago Department of Public Health, Southwest Senior Center, Pfizer, Moderna, U.S, EG, NYU, Vaccine, CNBC, Food and Drug Administration, Disease Control, CDC, World Health Organization Locations: Covid, Chicago , Illinois, Novavax, U.S

☆ Peter Loftus — Special Writer at The Wall Street Journal
▼ + stars: | 2023-08-17 | by ( Peter Loftus | ) www.wsj.com time to read: +1 min

Peter LoftusPeter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device industries. He has written about Covid-19 vaccines, advances in cancer treatments, drug shortages and the use of mobile devices in healthcare. Peter is the author of "The Messenger: Moderna, the Vaccine, and the Business Gamble That Changed the World," published in 2022 by Harvard Business Review Press. Before joining the Journal in 2013, he was a reporter for Dow Jones Newswires since 1997, covering the pharmaceutical and technology industries. He previously worked as a courthouse reporter at the Reporter newspaper in Lansdale, Pa.

Persons: Peter Loftus Peter Loftus, Peter, Dow Jones Newswires Organizations: Wall Street, Harvard Business Review Press, Reporter, University of Notre Dame Locations: Philadelphia, Lansdale, Pa

☆ Stock Market Today: Dow, Nasdaq Open Higher; Cisco, Walmart Stocks in Focus
▼ + stars: | 2023-08-17 | by ( ) www.wsj.com time to read: +1 min

Ten-year Treasury yields are up again after settling at their highest level since 2008, an ascent that is raising concern on Wall Street about the potential fallout for stocks. Yields have been driven up mostly by the strength of the U.S. economy, and the prospect of inflation remaining stubbornly high. Stocks were in the red following two days of losses spurred in part by higher yields. The S&P 500 and Dow industrials were modestly lower, while the Nasdaq Composite was off about 0.5%. Ten-year Treasury yields rose above 4.3%, after settling at 4.258% Wednesday.

Persons: Stocks, Dow industrials Organizations: Labor Department, Retail, Walmart, Nasdaq, Hawaiian Electric, Moderna, Global, Japan’s Nikkei Locations: U.S, Maui, Europe, Shanghai

☆ Pfizer's updated COVID shot effective against 'Eris' variant in mice study
▼ + stars: | 2023-08-17 | by ( ) www.reuters.com time to read: +1 min

Pfizer, along with its German partner BioNTech SE (22UAy.DE), as well as other COVID-19 vaccine makers Moderna (MRNA.O) and Novavax (NVAX.O) have created versions of their shots, which are aimed at the XBB.1.5 subvariant. EG.5, nicknamed by some as "Eris", is similar to the XBB.1.5 subvariant and a sub-lineage of the still-dominant Omicron variant. EG.5 accounted for about more than 17% of COVID-19 cases in the United States, according to the latest government data. In the United States, COVID-19 related hospitalizations are up more than 40% off of recent lows hit in June, but are still more than 90% below peak levels hit during the January 2022 Omicron outbreak. Reporting by Pratik Jain in Bengaluru; Editing by Shilpi MajumdarOur Standards: The Thomson Reuters Trust Principles.

Persons: Chris Aluka Berry, BioNTech, Pratik Jain, Shilpi Majumdar Organizations: Dekalb Pediatric Center, REUTERS, Pfizer, Pfizer Inc, Moderna, EG, World Health Organization, Thomson Locations: Dekalb, Georgia, Decatur , Georgia, U.S, United States, China, South Korea, Japan, Canada, Bengaluru

☆ Moderna says new Covid vaccine was effective against Eris variant in early trial
▼ + stars: | 2023-08-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Moderna's new Covid vaccine generated a robust immune response against the now-dominant Eris variant and another rapidly spreading strain of the virus in an early clinical trial, the biotech company said Thursday. The updated shot is designed to target omicron subvariant XBB.1.5, but the results suggest that the jab may still be effective against newer variants of the virus that are gaining ground nationwide. That includes Eris and another variant nicknamed Fornax, both of which are also descendants of the omicron virus variant. The World Health Organization designated Eris a "variant of interest," meaning it will be monitored for mutations that could make it more severe. A Pfizer spokesperson on Thursday said the company's own updated Covid shot effectively neutralized XBB.1.5 and Eris, among other variants, in a recent trial on mice.

Persons: Eris Organizations: omicron, Pfizer, Novavax, U.S . Food, Drug Administration, EG, Centers for Disease Control, World Health Organization, CDC Locations: U.S

☆ Moderna's updated COVID vaccine effective against 'Eris' variant in humans
▼ + stars: | 2023-08-17 | by ( ) www.reuters.com time to read: +2 min

Vials of the Moderna COVID-19 vaccine are seen at Apotex pharmaceutical company as Humber River Hospital's mobile vaccine clinic vaccinate employees as part of the coronavirus disease (COVID-19) vaccination campaign, in Toronto, Ontario, Canada April 13, 2021. REUTERS/Carlos Osorio/File Photo Acquire Licensing RightsCompanies BioNTech SE FollowModerna Inc FollowNovavax Inc Follow Show more companiesAug 17 (Reuters) - Moderna (MRNA.O) said on Thursday an initial study data showed its updated COVID-19 vaccine to be effective against the "Eris" and "Fornax" subvariants in humans. Moderna and other COVID-19 vaccine makers Novavax (NVAX.O), Pfizer (PFE.N) and German partner BioNTech SE (22UAy.DE) have created versions of their shots aimed at the XBB.1.5 subvariant. Earlier on Thursday, Pfizer reported that its updated COVID-19 shot, co-developed with BioNTech, showed neutralizing activity against the Eris subvariant in a study conducted on mice. Eris, the nickname for EG.5, is similar to the XBB.1.5 subvariant and a sub-lineage of the still-dominant Omicron variant.

Persons: Carlos Osorio, BioNTech, Pratik Jain, Shilpi Majumdar Organizations: Moderna, REUTERS, Pfizer, EG, Omicron, World Health Organization, Thomson Locations: Humber, Toronto , Ontario, Canada, United States, Europe, U.S, Bengaluru

☆ Piper Sandler's Craig Johnson breaks down the technicals of NVDA, ANF, MRNA & MSFT
▼ + stars: | 2023-08-16 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPiper Sandler's Craig Johnson breaks down the technicals of NVDA, ANF, MRNA & MSFTCraig Johnson, Piper Sandler, joins 'Power Lunch' to discuss technical support for Nvidia, Abercrombie & Fitch, Moderna and Microsoft.

Persons: Piper Sandler's Craig Johnson, MSFT Craig Johnson, Piper Sandler Organizations: Nvidia, Abercrombie, Fitch, Moderna, Microsoft

☆ Catalent, facing pressure from Elliott, had other activists in stock
▼ + stars: | 2023-08-14 | by ( Svea Herbst-Bayliss | ) www.reuters.com time to read: +2 min

A general view of the drug product manufacturing laboratory in biologics and sterile injectables, Catalent, in Brussels, Belgium June 27, 2023. Keith Meister's Corvex Management and Scott Ferguson's Sachem Head Capital Management each disclosed buying Catalent stock in the second quarter and owning it on June 30. Corvex initiated a new position in Catalent, buying 5.7 million shares during the second quarter, while Sachem Head purchased 662,000 shares during the quarter, also a new position for the fund. While Elliott is among the world's most prominent and busiest activist investors, both Corvex and Sachem Head have in the past targeted other companies and successfully lobbied for board seats. Representatives for Corvex and Sachem Head declined to comment beyond the filings.

Persons: Yves Herman, Keith Meister's, Scott Ferguson's, Corvex, Elliott, Catalent, Svea Herbst, Bayliss, Sonali Paul Organizations: REUTERS, Elliott Investment Management, Management, Capital Management, Sachem, Corvex, AstraZeneca, Johnson, Moderna, Svea, Thomson Locations: Brussels, Belgium, Catalent, Europe, United States

☆ New Covid vaccines are on the way as 'Eris' variant rises
▼ + stars: | 2023-08-14 | by ( Michael Erman | ) www.reuters.com time to read: +5 min

Some public health experts hope that Americans will welcome the new shot as they would a flu jab. In the fall of 2022, by which time most people had either had the COVID virus or the vaccine, fewer than 50 million people got the shots. Its biggest rival, Moderna, conceded demand could be as few as 50 million shots. POST PANDEMIC VACCINEThe COVID public health emergency ended in May and the government has handed much of the duty of vaccinating America to the private sector. As with the flu, Pfizer (PFE.N)/BioNTech SE (22UAy.DE), Moderna (MRNA.O) and Novavax (NVAX.O), have created versions of the COVID vaccine to try to match the variant they believe will be circulating this fall.

Persons: Dado Ruvic, Ashley Kirzinger, Kirzinger, BioNTech, Jefferies, Michael Yee, " Yee, Mandy Cohen, William Schaffner, Schaffner, David Boulware, Michael Erman, Caroline Humer, Diane Craft Organizations: REUTERS, CVS Health, Family, Reuters, Pfizer –, Moderna, Pfizer, U.S . Centers for Disease Control, Prevention, CDC, U.S . Food, Drug Administration, EG, Vanderbilt University, University of Minnesota, Thomson Locations: U.S, America, United States, COVID, CDC's

☆ Covid Eris: What to know about new variant EG.5 dominating U.S. cases
▼ + stars: | 2023-08-14 | by ( Michael Erman | ) www.reuters.com time to read: +2 min

NEW YORK, Aug 14 (Reuters) - COVID infections and hospitalizations are on the rise in the U.S., Europe and Asia. Health officials are pointing at the EG.5 "Eris" coronavirus, a subvariant of the Omicron lineage that originally emerged November of 2021. EG.5 had been found in more than 50 countries as of August 8, according to the WHO. It is the most common and fastest growing COVID-19 subvariant in the U.S., estimated to be responsible for around 17% of current COVID cases, according to the CDC. EG.5 is similar to XBB.1.5 although the newer subvariant carries one mutation to its spike protein, the part of the virus targeted by the vaccine.

Persons: Mandy Cohen, Cohen, Michael Erman, Caroline Humer, Diane Craft Organizations: Health, EG, Omicron, World Health Organization, WHO, CDC, Pfizer, Thomson Locations: U.S, Europe, Asia

☆ SolarEdge is among the most oversold stocks in the S&P 500. Here are the others
▼ + stars: | 2023-08-12 | by ( Pia Singh | ) www.cnbc.com time to read: +4 min

Following this week's moves, CNBC Pro used FactSet data to screen for the most overbought and oversold names in the S & P 500 based on their 14-day relative strength index, or RSI. Here are some of the most oversold names: SolarEdge is one of the most oversold companies in the S & P 500. NextEra Energy had the highest number of analyst buy ratings among the stocks on the oversold list, according to CNBC's screen. Meanwhile, the following 10 stocks are the most overbought in the S & P 500: Marathon Petroleum is the most overbought stock in the broad-based index, with an RSI of 96.3. Oilfield servicer Halliburton Company , Cessna aircraft maker Textron and construction services provider Jacobs Solutions are also among the most overbought companies in the S & P 500.

Persons: Dow Jones Industrials, SolarEdge Organizations: SolarEdge Technologies, Nasdaq, Nvidia, Micron, CNBC Pro, Street, NextEra Energy, Moderna, GE Healthcare Technologies, Ameren Corporation, Enphase Energy, Marathon Petroleum, Biotech, Global Payments, Jefferies, servicer Halliburton Company, Cessna, Textron, Jacobs Solutions Locations: Florida, Cambridge , Massachusetts

☆ With Eris on the rise, US CDC sees no major shift in COVID variants
▼ + stars: | 2023-08-09 | by ( ) www.reuters.com time to read: +2 min

Updated vaccines should be available by mid- to late September, she said. The vaccines still need to be authorized by the U.S. Food and Drug Administration and the CDC needs to make its recommendations, she said. "We are likely to see this as a recommendation as an annual COVID shot just like we have an annual flu shot," she said. Pfizer (PFE.N)/BioNTech SE (22UAy.DE), Moderna (MRNA.O) and Novavax (NVAX.O) have all said they expect to have supplies of the updated vaccine ready for the roll out this autumn. Eris is the fasting-growing COVID-19 subvariant in the U.S., estimated to be responsible for around 17% of current COVID cases, according to the CDC.

Persons: Mandy Cohen, Biden, Andy Slavitt's, we've, Cohen, Michael Erman, Lisa Shumaker Organizations: EG, U.S . Centers for Disease Control, U.S . Food, Drug Administration, Pfizer, World Health Organization, CDC, Thomson Locations: United States, China, U.S, New York

In a filing to Shanghai's stock exchange, CanSino said it would manufacture and supply unspecified mRNA products to AstraZeneca. AstraZeneca said the deal would support investigational mRNA vaccines in its early pipeline. The country approved in March its first homegrown mRNA vaccine against COVID, developed by CSPC Pharmaceutical Group (1093.HK). CanSino has been working on its own mRNA COVID vaccine, and said in February it was in discussion with Chinese regulators around the protocol for a late-stage study for its COVID mRNA booster vaccine, CS-2034. It also comes after vaccine maker Moderna (MRNA.O), which has said that it was keen to sell its mRNA vaccine to China, announced a deal last month to develop and manufacture mRNA medicines in the country.

Persons: Dado Ruvic, Biologics, CanSino, Wang Wentao, Casey Hall, Ludwig Burger, Miyoung Kim, Mark Potter, Himani Organizations: AstraZeneca, REUTERS, HK, CSPC Pharmaceutical, CS, Communist Party, China's Commerce, Moderna, Thomson Locations: Swedish, China, Frankfurt

☆ Goldman names stocks with the greatest alpha opportunities, including one with 70% upside
▼ + stars: | 2023-08-07 | by ( Samantha Subin | ) www.cnbc.com time to read: +2 min

Microeconomic factors seem to be dominating the market action in 2023, and Goldman Sachs is offering up some opportunities to capture the greatest alpha in this environment. Options pricing also reflects expectations for elevated return dispersion over the near term, Goldman Sachs chief U.S. equity strategist David Kostin said in a Friday note. Consensus expectations call for the median stock on the list to rise 24%, versus 11% expected for the median S & P 500 stock. "These stocks ultimately present alpha generating opportunities for investors to apply directional views on fundamental outlooks or near-term catalysts," Kostin wrote. Goldman also included solar stock Enphase Energy , down more than 49% year to date.

Persons: Goldman Sachs, David Kostin, Goldman, Kostin, — CNBC's Michael Bloom Organizations: Wall, Moderna, Technologies, Energy, Netflix, Goldman

☆ Here are Friday's biggest analyst calls: Apple, Amazon, Coinbase, Generac, Wayfair, Disney & more
▼ + stars: | 2023-08-04 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Morgan Stanley reiterates Apple as overweight Morgan Stanley said it's standing by its overweight rating on Apple after its earnings report Thursday. Rosenblatt downgrades Apple to neutral from buy Rosenblatt said Apple is sitting in a "slowdown phase." Citi upgrades Intercontinental Exchange to buy from neutral Citi said it sees "improving signals across the platform" for the exchange company. Citi opens a positive catalyst watch on Apple Citi said it sees upside ahead of the company's new iPhone unveil in September. Citi reiterates Disney as buy Citi said it's sticking with its buy rating on stock heading into earnings next week. "

Persons: Stephens, it's, Morgan Stanley, Apple, tonight's, Rosenblatt, Raymond James, Goldman Sachs, Goldman, Oppenheimer, Tim Horton's, TD Cowen, Read, Truist, Lamb Weston, Stifel, Evercore Organizations: bil, Bank of America, AWS, underperform Bank of America, Apple, AMD, Citi, Intercontinental Exchange, ICE, Galactic, Virgin Galactic, Brands, Restaurant Brands, SSS, TH, BK, TD Cowen downgrades Moderna, Apple Citi, Disney, JPMorgan, Petrobras, Petrobras –, PayPal Locations: Coinbase, Burger, F1Q23

Search resuls for: "Moderna"

25 mentions found